BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Guoli Chen, Zhaohai Yang, James R. Eshleman, George J. Netto, Ming-Tseh Lin. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveBioMed Research International 2016; 2016: 1 doi: 10.1155/2016/9850690
2
André F. Oliveira, Luís Bretes, Irene Furtado. Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal CancerFrontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00396
3
Zoran Gatalica, Semir Vranic, Joanne Xiu, Jeffrey Swensen, Sandeep Reddy. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicineFamilial Cancer 2016; 15(3): 405 doi: 10.1007/s10689-016-9884-6
4
Christine Böger, Hans-Michael Behrens, Micaela Mathiak, Sandra Krüger, Holger Kalthoff, Christoph Röcken. PD-L1 is an independent prognostic predictor in gastric cancer of Western patientsOncotarget 2016; 7(17): 24269 doi: 10.18632/oncotarget.8169
5
Leon Chen, Alexander B. Aria, Sirunya Silapunt, Michael R. Migden. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin CancerDermatologic Surgery 2019; 45(1): 1 doi: 10.1097/DSS.0000000000001601
6
Paula Baraúna Assumpção, Erika Couto Canelas, Aline Cruz Ramos, Ana Anaissi, João Felipe Acioli, Geraldo Ishak, Sidney Santos, Samia Demachki, Paulo Assumpção. Lymph nodes may be a source for immunetherapy in gastric cancerOncotarget 2020; 11(19): 1729 doi: 10.18632/oncotarget.27578
7
Minyu Wang, Rita A Busuttil, Sharon Pattison, Paul J Neeson, Alex Boussioutas. Immunological battlefield in gastric cancer and role of immunotherapiesWorld Journal of Gastroenterology 2016; 22(28): 6373-6384 doi: 10.3748/wjg.v22.i28.6373
8
Huan Bin Wang, Han Yao, Chu Shu Li, Lun Xi Liang, Yao Zhang, Ying Xuan Chen, Jing-Yuan Fang, Jie Xu. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapyJournal of Digestive Diseases 2017; 18(10): 574 doi: 10.1111/1751-2980.12538
9
Esmeralda Celia Marginean, Barbara Melosky. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal CancerArchives of Pathology & Laboratory Medicine 2018; 142(1): 26 doi: 10.5858/arpa.2017-0041-RA
10
Lingyu Li, Wei Li, Chang Wang, Xu Yan, Yizhuo Wang, Chao Niu, Xiaoying Zhang, Min Li, Huimin Tian, Cheng Yao, Haofan Jin, Fujun Han, Dongsheng Xu, Wei Han, Dan Li, Jiuwei Cui. Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinomaCytotherapy 2018; 20(1): 134 doi: 10.1016/j.jcyt.2017.09.009
11
Hamzah Abu-Sbeih, Yinghong Wang. ImmunotherapyAdvances in Experimental Medicine and Biology 2020; 1244: 247 doi: 10.1007/978-3-030-41008-7_12
12
Ye Hong, Zhen-Yu Ding. PD-1 Inhibitors in the Advanced Esophageal CancerFrontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.01418
13
Petra Hudler, Radovan Komel. Gastric Cancer2017;  doi: 10.5772/intechopen.69775
14
L Liu, Y Wang, R Bai, K Yang, Z Tian. MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α regulationOncogenesis 2016; 5(5): e224 doi: 10.1038/oncsis.2016.35
15
James W.T. Toh, Paul de Souza, Stephanie H. Lim, Puneet Singh, Wei Chua, Weng Ng, Kevin J. Spring. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor TherapyClinical Colorectal Cancer 2016; 15(4): 285 doi: 10.1016/j.clcc.2016.07.007
16
Zheyu Song, Yuanyu Wu, Jiebing Yang, Dingquan Yang, Xuedong Fang. Progress in the treatment of advanced gastric cancerTumor Biology 2017; 39(7): 101042831771462 doi: 10.1177/1010428317714626
17
Junhun Cho, Kyoung-Mee Kim, Hee Cheol Kim, Woo Yong Lee, Won ki Kang, Young Suk Park, Sang Yun Ha. The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinomaPathology - Research and Practice 2019; 215(1): 171 doi: 10.1016/j.prp.2018.10.024
18
Naoki Takahashi, Satoru Iwasa, Yusuke Sasaki, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Natsuko Tsuda Okita, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancerJournal of Cancer Research and Clinical Oncology 2016; 142(8): 1727 doi: 10.1007/s00432-016-2184-6
19
Xiaofang Xing, Jianping Guo, Guangyu Ding, Bo Li, Bin Dong, Qin Feng, Shen Li, Jian Zhang, Xiaomin Ying, Xiaojing Cheng, Ting Guo, Hong Du, Ying Hu, Tao Zhou, Xiaohong Wang, Lin Li, Qingda Li, Meng Xie, Liting Li, Xiangyu Gao, Fei Shan, Ziyu Li, Shuqin Jia, Xianzi Wen, Jiping Wang, Jiafu Ji. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patientsOncoImmunology 2018; 7(3): e1356144 doi: 10.1080/2162402X.2017.1356144
20
David J. Birnbaum, François Bertucci, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer 2018; 1869(2): 248 doi: 10.1016/j.bbcan.2018.02.001
21
Ruiqi Liu, Ke Peng, Yiyi Yu, Li Liang, Xiaojing Xu, Wei Li, Shan Yu, Tianshu Liu. Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative OperationBioMed Research International 2018; 2018: 1 doi: 10.1155/2018/5920608
22
Yun Tian, Hamzah Abu-Sbeih, Yinghong Wang. ImmunotherapyAdvances in Experimental Medicine and Biology 2018; 995: 151 doi: 10.1007/978-3-030-02505-2_7
23
Apostolos Zaravinos, Constantinos Roufas, Majdi Nagara, Beatriz de Lucas Moreno, Maria Oblovatskaya, Christodoulos Efstathiades, Christos Dimopoulos, Georgios D. Ayiomamitis. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancerJournal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1372-z
24
Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal CancerCancers 2019; 11(10): 1567 doi: 10.3390/cancers11101567
25
Giuseppe Ercolano, Maryline Falquet, Giulia Vanoni, Sara Trabanelli, Camilla Jandus. ILC2s: New Actors in Tumor ImmunityFrontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.02801
26
Sheik Emambux, Gaelle Tachon, Audelaure Junca, David Tougeron. Results and challenges of immune checkpoint inhibitors in colorectal cancerExpert Opinion on Biological Therapy 2018; 18(5): 561 doi: 10.1080/14712598.2018.1445222
27
Kyung-Ju Kim, Han Kwang Yang, Woo Ho Kim, Gyeong Hoon Kang. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancersOncotarget 2017; 8(35): 58887 doi: 10.18632/oncotarget.19439
28
Basile Tessier-Cloutier, Steve E. Kalloger, Mohammad Al-Kandari, Katy Milne, Dongxia Gao, Brad H. Nelson, Daniel J. Renouf, Brandon S. Sheffield, David F. Schaeffer. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinomaBMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3634-5
29
Qingfang Zhao, Liang Cao, Lulu Guan, Liangyu Bie, Saiqi Wang, Bojian Xie, Xiaobing Chen, Xiaokun Shen, Feiling Cao. Immunotherapy for gastric cancer: dilemmas and prospectBriefings in Functional Genomics 2019; 18(2): 107 doi: 10.1093/bfgp/ely019
30
Simon Pernot, Toulsie Ramtohul, Julien Taieb. Checkpoint inhibitors and gastrointestinal immune-related adverse eventsCurrent Opinion in Oncology 2016; 28(4): 264 doi: 10.1097/CCO.0000000000000292
31
Shenying Jin, Bo Xu, Lixia Yu, Yao Fu, Hongyan Wu, Xiangshan Fan, Jia Wei, Baorui Liu. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapyOncotarget 2017; 8(24): 38850 doi: 10.18632/oncotarget.16407